This review will cover recent advances in the field of medicinal chemistry towards small-molecule BTK inhibitors under clinical trials for the treatment of inflammatory and autoimmune diseases, including RA, SS, MS, SLE, urticaria, pemphigus, ITP, and RD. This evidence concerns the gene BTK and rheumatoid arthritis.